Seeking Alpha


Send Message
View as an RSS Feed
View findingZzero's Comments BY TICKER:
Latest  |  Highest rated
  • Eli Lilly: Zero Dividend Increases The Norm? [View article]
    1. See first comment.
    2. Would you prefer to own a company with a 2% dividend growing at 10% a year?
    Mar 5, 2015. 08:17 AM | Likes Like |Link to Comment
  • Eli Lilly: A Dividend Play And More [View article]
    When I worked at El Lilly (1982-2009) as a research scientist, John Lechleiter was usually the smartest guy in the room (and usually the one with the best sense of humor). I met him in 1982 when he was just leaving the lab to go into management. He knows the business from the bottom up. I can't think of anyone I would trust the future of the company to than he.
    Aug 5, 2014. 09:06 AM | 3 Likes Like |Link to Comment
  • Here's a quixotic twist: It appears that battling certain types cancer may lower the risk for developing Alzheimer's disease, new research suggests. After pouring over data, investigators have concluded that most kinds of cancer - with the exception of prostate cancer - seem to confer some degree of protection against Alzheimer's, reducing risk of the age-related brain disorder by anywhere from 9% to 51%. They've also linked a common form of cancer treatment, chemotherapy, to a lower risk for developing Alzheimer's-related dementia. [View news story]
    A cancer diagnosis concentrates the mind........
    Jul 16, 2013. 11:25 AM | Likes Like |Link to Comment
  • Eli Lilly (LLY) and Incyte (INCY) announce positive results from ongoing Phase IIb studies of baricitinib in patients with rheumatoid arthritis who had an inadequate response to treatment with methotrexate. Additionally, MRI technology was used in a sub-study to examine the effect of baricitinib on joint erosion and other markers of structural changes in and around the joint, which showed statistically significant improvement in both the Total Inflammation Score and the Total Joint Damage Score compared with placebo at 12 weeks. LLY +0.8%, INCY -0.9% AH. [View news story]
    Thanks for your comment. I thought those #'s were clinical trial #'s for joint erosion/inflammation, and wondered why Incyte and LLY were opposite. I need to realize this is a market website and not the Institute of Joint diseases. lol.....
    Nov 14, 2012. 12:34 PM | Likes Like |Link to Comment
  • Levels of beta amyloid, a protein linked with Alzheimer's, increased in the blood of patients treated with Eli Lilly's (LLY) solanezumab in two Phase III trials, suggesting that the protein was removed from the brain as intended. As already disclosed, Solanezumab seems to be able to slow Alzheimer's progression in patients with mild symptoms, so the latest finding provides validity to the belief that amyloid is a cause. [View news story]
    I remember when I started as a chemist in drug discovery, my mentor told me a cautionary tale about data interpretation. You might call it a pharmaceutical urban legend (from the '60's). A company was excited about an expt'l drug that dramatically lowered blood cholesterol, only to find that it was accumulating as plaque in the arteries. Be careful how you interpret the data.
    Oct 30, 2012. 02:12 PM | Likes Like |Link to Comment